Status:
RECRUITING
DFS and QOL After Modified Radical Mastectomy vs. Expanded Mckissock Surgery for EIC of the Breast
Lead Sponsor:
Shengjing Hospital
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
45-75 years
Phase:
NA
Brief Summary
Extensive intraductal carcinoma of the breast refers to a type of breast cancer in which ≥ 25% of ductal carcinoma in situ is present in invasive tumors and there is a scattered distribution of ductal...
Detailed Description
Extensive intraductal carcinoma of the breast refers to a type of breast cancer in which ≥ 25% of ductal carcinoma in situ is present in invasive tumors and there is a scattered distribution of ductal...
Eligibility Criteria
Inclusion
- Patients with extensive intraductal carcinoma confirmed by hollow needle biopsy;
- the lesion not involving the nipple as confirmed by enhanced MR imaging of the breast;
- Bra cup size: B or higher;
- postmenopausal patients;
- provision of written informed consent.
Exclusion
- The cutting edge of nipple-areola complex tested positive for extensive intraductal carcinoma twice;
- preoperative nipple hemorrhage;
- bilateral breast cancer;
- inflammatory breast cancer;
- distant metastasis;
- other cancers or those who receive chest radiotherapy.
Key Trial Info
Start Date :
October 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04052893
Start Date
October 1 2019
End Date
September 1 2026
Last Update
February 8 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
General Hospital of Benxi Iron & Steel Industry Group of Liaoning Health Industry Group
Benxi, Liaoning, China, 117000
2
Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute
Shengyang, Liaoning, China, 110042
3
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China, 110004